ADAP - Adaptimmune Therapeutics plc
| Previous Close | 4.2900 |
| Open | 4.3100 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 2200 |
| Day's Range | 3.9350 - 4.3400 |
| 52 Week Range | 3.5500 - 14.6250 |
| Volume | 302,059 |
| Avg. Volume | 264,051 |
| Market Cap | 431.413M |
| Beta (3Y Monthly) | 1.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9810 |
| Earnings Date | Mar 15, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- GlobeNewswire•3 days ago
Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
- Presentation to include overview of substantial progress of Adaptimmune’s off-the-shelf SPEAR T-cell platform - - Data will show that hiPSC-derived allogeneic SPEAR T-cells.
GuruFocus.com•9 days agoThese 3 Falling Knives Are Expected to Outperform
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NKTR. The closing price on Thursday was 22.5% off the 52-week low of $29.22 and 193% from the 52-week high of $104.88.
- GlobeNewswire•20 days ago
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
PHILADELPHIA and OXFORD, United Kingdom, April 02, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety.
- GlobeNewswire•21 days ago
Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
PHILADELPHIA and OXFORD, United Kingdom, April 01, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented promising.
- Simply Wall St.•last month
Does Adaptimmune Therapeutics plc (NASDAQ:ADAP) Have A Particularly Volatile Share Price?
If you're interested in Adaptimmune Therapeutics plc (NASDAQ:ADAP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ADAP earnings conference call or presentation 27-Feb-19 1:00pm GMT
Q4 2018 Adaptimmune Therapeutics PLC Earnings Call
- GlobeNewswire•2 months ago
Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
- On track for clinical data update from trials in multiple solid tumors at the Q1 2019 earnings update call in May - - Completed initial safety cohorts for ADP-A2M10.
- Simply Wall St.•2 months ago
Should You Worry About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) CEO Salary Level?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! James Noble became the CEO of AdaptimmuneRead More...
- GlobeNewswire•2 months ago
Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
PHILADELPHIA and OXFORD, United Kingdom, Feb. 07, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial.
- Zacks•3 months ago
Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks•3 months ago
Radius Exceeds 2018 Financial Guidance, Provides Updates
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
- Zacks•3 months ago
Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.
- GlobeNewswire•3 months ago
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the.
- Simply Wall St.•4 months ago
What Percentage Of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Do Insiders Own?
The big shareholder groups in Adaptimmune Therapeutics plc (NASDAQ:ADAP) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...
- GlobeNewswire•4 months ago
Adaptimmune Announces that Gwen Binder will leave in January 2019
PHILADELPHIA and OXFORD, United Kingdom, Dec. 12, 2018 -- Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder, PhD, Chief.
- GlobeNewswire•5 months ago
Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT
Q3 2018 Adaptimmune Therapeutics PLC Earnings Call
Market Realist•5 months agouniQure Stock Rose 35.7% Yesterday—Here’s Why
On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.
- Simply Wall St.•5 months ago
What You Must Know About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) Financial Strength
Adaptimmune Therapeutics plc (NASDAQ:ADAP), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is ADAP Read More...
- GlobeNewswire•5 months ago
Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells.
- Motley Fool•6 months ago
3 Beaten-Down Biotech Stocks: Can They Bounce Back?
See if these oncology-driven drugmakers have what it takes to recover from recent setbacks.
- Zacks•6 months ago
Adaptimmune Therapeutics Worldwide Enters Oversold Territory
Adaptimmune Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
